

References:

1. Summary of product characteristics in KSA on Saudi Drugs Information system (SDI) website: (<https://sdi.sfda.gov.sa/>).
2. Diabetes UK, 2024. Side effects of insulin. [online] Available at: <https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/insulin/side-effects> [Accessed 20 September 2024].

Disclaimer:

This educational guide is designed for informational and risk minimisation purposes only and should not be construed as promotional or marketing material.

Kindly report side effects through the following channels:

- Saudi Food & Drug Authority (SFDA):

SFDA Call Center: 19999

E-mail: npc.drug@sfda.gov.sa

Website: <http://ade.sfda.gov.sa/>

- Novo Nordisk Saudi Arabia:

E-mail: nngulfsafety@novonordisk.com

Website: <https://www.novonordisk.com.sa/>



Levemir® is a registered trademark of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2024 Novo Nordisk All rights reserved.




Important Risk Minimization Information for Patients:

Phase-out of Levemir® (Insulin Detemir)

1. This information is intended for patients with diabetes who have been prescribed Levemir®. This transition ensures patients continue to receive the best treatment options.
2. You should speak to your doctor at the earliest opportunity to discuss alternative treatment options suitable for you and to prepare for the switch of insulins.

This leaflet provides information on the phase-out of Levemir® by Novo Nordisk and what this means for you.




Why Novo Nordisk is phasing out Levemir®

Novo Nordisk wants to deliver medicines that will benefit and ultimately best serve the greatest number of patients globally. Due to the increasing number of people suffering from diabetes and our need to better meet patient demand with a stable product supply, we are consolidating our portfolio.

As a result, Levemir® will be phased out globally.

The top priority of Novo Nordisk is always the health and safety of the patients. The decision to phase out basal insulin like Levemir® was made after careful consideration and is not a consequence of any safety or quality related issues. Novo Nordisk remains committed to providing support and information to healthcare professionals throughout this process to ensure continuity of care.



When will my insulin be phased out?

- In Saudi Arabia, Levemir® will be phased out by 2026.
- You should speak to your doctor at the earliest opportunity to switch to an alternative insulin to avoid any interruptions to your treatment.

Levemir® is being phased out. What should my next steps be?

- Your doctor should monitor you closely as you switch to a new insulin to ensure a safe transition.
- Your doctor will help you switch to a different insulin using their clinical judgement, awareness of your medical history and individual needs, and knowledge of what products are available in your country.

What to consider when switching insulins:

- As with all prescribed medication, everyone reacts differently.
- Check the patient information leaflet supplied with your insulin to see what the side effects are. Remember, you're unlikely to experience all of them.
- You should let your healthcare professional know if you have headaches, nausea or flu-like symptoms within the first 72 hours of starting any new insulin.